Bank of Nova Scotia Purchases Shares of 44,200 Natera, Inc. $NTRA

Bank of Nova Scotia purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 44,200 shares of the medical research company's stock, valued at approximately $11,998,000.

Other institutional investors have also recently made changes to their positions in the company. Trust Co. of Vermont bought a new position in Natera in the second quarter worth approximately $26,000. Elevation Wealth Partners LLC bought a new stake in Natera during the second quarter valued at about $30,000. Reflection Asset Management bought a new stake in Natera during the fourth quarter valued at about $29,000. Rakuten Securities Inc. purchased a new stake in Natera in the second quarter worth about $35,000. Finally, Palladiem LLC purchased a new stake in Natera in the fourth quarter worth about $31,000. Institutional investors own 99.90% of the company's stock.

Insider Transactions at Natera

In other news, insider Solomon Moshkevich sold 3,410 shares of the company's stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80. Following the sale, the insider directly owned 129,019 shares of the company's stock, valued at $34,264,866.02. This represents a 2.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 3,076 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $266.39, for a total value of $819,415.64. Following the transaction, the chief executive officer owned 99,897 shares of the company's stock, valued at $26,611,561.83. This represents a 2.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 177,955 shares of company stock valued at $40,704,193 over the last three months. Corporate insiders own 5.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Stephens lifted their price objective on Natera from $305.00 to $350.00 and gave the company an "overweight" rating in a research report on Wednesday, August 12th. Morgan Stanley reaffirmed an "overweight" rating and set a $355.00 price target on shares of Natera in a report on Monday, August 10th. Guggenheim upped their price target on shares of Natera from $290.00 to $360.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. Piper Sandler increased their price objective on shares of Natera from $249.00 to $363.50 and gave the stock an "overweight" rating in a research note on Wednesday, August 12th. Finally, Canaccord Genuity Group set a $375.00 price objective on shares of Natera in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $319.38.

Natera Price Performance

NTRA stock opened at $327.72 on Tuesday. Natera, Inc. has a 1-year low of $157.43 and a 1-year high of $333.56. The business has a 50 day simple moving average of $276.45 and a two-hundred day simple moving average of $230.09. The company has a market capitalization of $47.24 billion, a price-to-earnings ratio of -240.97 and a beta of 1.51.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. The firm had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company's quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.74) earnings per share. Sell-side analysts anticipate that Natera, Inc. will post -1.02 EPS for the current fiscal year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source